Chemotherapy is a cornerstone option in cancer treatment owing to its efficacy and effect on quality of life of cancer patients. The action mechanism of anticancer agents is targeted at deregulating cell cycle machinery and inhibiting unscheduled proliferation of cancer cells (Lin et al., 2020). Unfortunately, chemotherapeutic anticancer drugs often exert deleterious effect on healthy cells and tissues leading to systemic toxicity (Negrette-Guzmán, 2019). The toxicity may become unbearable that the treatment regimen has to be disrupted, even when achieving tumoricidal efficacy (Lin et al., 2020). Cisplatin (CIS) is an efficacious anticancer agent; it is the first choice for the treatment of advanced nonsmall-cell lung cancer cells, breast cancer and ovarian cancer (Browning et al., 2017; Lin et al., 2020; Manohar & Leung, 2018). It is of significant value also in the treatment of germ cell and testicular cancers (Thurston, 2007). It unleashes its anticancer action through formation of cisplatin-DNA adduct by intrastrand cross-links due to interaction with cancer cell DNA purine bases eventually leading to p53 activation, cell cycle arrest and induction